Showing 7261-7270 of 7932 results for "".
- Envy Medical Launches SilkPeel Daily Dermal Optimizerhttps://practicaldermatology.com/news/envy-medical-launches-silkpeel-daily-dermal-optimizer/2458663/Envy Medical, Inc., is launching its SilkPeel® Daily Der al Optimizer at the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, DC. Building off of the professional SilkPeel Diamo
- Lumenis Supports the Launch of Restoring Heroes Foundation for Scar Patientshttps://practicaldermatology.com/news/lumenis-launches-restoring-heroes-foundation-for-scar-patients/2458658/Kim Phuc, the young girl who was immortalized in a photograph taken during the 1972 Napalm bombing, has come a long way since that fateful day. When the photo was taken, she was running away from her village, naked, after her clothing had been burnt off. South Vietnamese plane
- Cool Change: New CoolSculpting Apps Slash Treatment Timehttps://practicaldermatology.com/news/cool-change-new-coolsculpting-apps-slash-treatment-time/2458666/ZELTIQ® Aesthetics, Inc. is welcoming a new family of applicators called CoolAdvantage™ at the American Academy of Dermatology Annual Meeting in Washington, D.C. The CoolAdvantage applicator delivers CoolSculpting
- Vitiligo Working Group Launches Public Awareness Campaignhttps://practicaldermatology.com/news/vitiligo-working-group-launches-public-awareness-campaign/2458665/The Vitiligo Working Group is drawing attention to the many faces of vitiligo with a new public awareness campaign. This initiative rolls out at the 74th Annual Meeting of the American Academy of Dermatology (AAD) in Washington, DC.
- Valeant Pharmaceuticals Comments On Management Changehttps://practicaldermatology.com/news/valeant-pharmaceuticals-comments-on-management-change/2458668/Valeant Pharmaceuticals International, Inc. today issued the following comments in response to inquiries from investors regarding Deb Jorn's departure from Valeant.
- Provectus Biopharmaceuticals Announces Leadership Changeshttps://practicaldermatology.com/news/provectus-biopharmaceuticals-announces-leadership-changes/2458674/Provectus Biopharmaceuticals, Inc. detailed several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD. The Provectus Board of Directors accepted the resignation of Dr. Dees, which he submitted due to personal and health reasons, in
- Grooming Habits, Products May Affect Alopecia Riskhttps://practicaldermatology.com/news/grooming-habits-products-may-affect-alopecia-risk/2458671/Environmental factors --including weathering and grooming habits – may play a role in causing age-related alopecia, according to a new report in the International Journal of Women’s Dermatolog
- Practical Dermatology® Launches #PDGivesBack to Support Camp Discovery at AAD 2016https://practicaldermatology.com/news/practical-dermatology-launches-pdgivesback-to-support-camp-discovery-at-aad-2016/2458672/Bryn Mawr Communications III’s Practical Dermatology® magazine is inviting attendees at the 74th Annual Meeting of the American Academy of Dermatology (AAD) to give back as part of its new “selfless-selfies” campaign.
- Novel Nanotechnology Delivery System May Offer New Approach to Skin Disease Treatmenthttps://practicaldermatology.com/news/novel-nanotechnology-delivery-system-may-offer-new-approach-to-skin-disease-treatment/2458675/A new nanotechnology-based delivery system may help activate the body's natural defense against free radicals and control a variety of skin conditions, report researchers from The Hebrew University of Jerusalem and Technion -- Israel Institute of Technology. Specifically, applyi
- Valeant Pharmaceuticals Announces Management And Business Updatehttps://practicaldermatology.com/news/valeant-pharmaceuticals-announces-management-and-business-update/2458677/J. Michael Pearson has returned as Valeant Pharmaceuticals International, Inc.’s chief executive officer following his recovery from severe pneumonia and other complications. Howard B. Schiller, Valeant's interim chief executive officer, will transition out of his current duties but wil